Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M{\LdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBOVAuOTBizszN MVqwMVQh\A>? M2jkc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGHvfmQzPjdyMke4OC=>
HepG2 NXjuSZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:2NE0yOCEQvF2= MXWwMVQh\A>? M33uT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml;uNlY4ODJ5OES=
HT29 NWK3N4VWTnWwY4Tpc44hSXO|YYm= MXO1NOKhdk1? M3r2[|I1NTd{IHi= NYPWXXhRcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh M{LvVVI3PzB{N{i0
HepG2 M4G2VWZ2dmO2aX;uJGF{e2G7 M4jNVlUxyqCwTR?= NYLFSFBJOjRvN{KgbC=> MmLobY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkAzPMLiaNMg NVnzPYR6OjZ5MEK3PFQ>
HCC827 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTSfppCPS95LkWvNVAhdk1? Ml64O|LDqGh? Moq0SG1UVw>? MnvP[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? Ml7tNlY3PzV2OES=
A549  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyNVAwOTVxMkCgcm0> NFzVVJM4OsLiaB?= NVjYV3d7TE2VTx?= M4e2O4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk M{jRcFI3Pjd3NEi0
NCI-H460  NI\DfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nVOVExNzJyL{OwJI5O NXzwfWxMPzMEoHi= NE\TZ2dFVVOR MU\lcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? M1LqVFI3Pjd3NEi0
J89GFP M4DCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWySG1UV8Li M4PtbmVEPTB;NEmuPFUhyrFiMUKuOlUhdk1? M{i2NFI3PTZ|NU[4
THP89GFP MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHEUXNQyqB? MmTFSWM2OD1zOT6zOEDDuSB4LkSzJI5O MVWyOlU3OzV4OB?=
SK-NEP-1 NWfobHVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H4bVAvODIkgKOxNE4xKM7:TR?= NFy3TIgzPCCq NUfIW3J6TE2VT9Mg MYnJR|UxRTd4LkO0JI5O M3zLWFI3OTd4MkG5
G401 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyfXkxNjBz4pETNVAvOCEQvF2= MkDhNlQhcA>? NVzPeWxnTE2VT9Mg NVHVWod[UUN3ME2xOFMvODJibl2= M3LYW|I3OTd4MkG5
SK-NEP-1 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV;udmkyPTBibl2= MWmx5qCUPCCm MnPRSG1UV8Li M3TuOJJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NHTEb4wzPjF5NkKxPS=>
G401 NF64fmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkjYOVAhdk1? MX2x5qCUPCCm NETsW4lFVVORwrC= Ml61doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NVLs[XhwOjZzN{[yNVk>
SK-NEP-1 M1v0XmFxd3C2b4Ppd{BCe3OjeR?= MknnOVAwOTByIH7N MVKyOEBp MoPkSG1UV8Li MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1SxbFI3OTd4MkG5
G401 M122SGFxd3C2b4Ppd{BCe3OjeR?= NXvFS4g4PTBxMUCwJI5O NXG0V2hVOjRiaB?= MX7EUXNQyqB? NYXRO3pYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkPjNlYyPzZ{MUm=
SK-NEP-1 MX;GeY5kfGmxbjDBd5NigQ>? MVO1NE8yODBibl2= MVeyOEBp MnnpSG1UV8Li M2L5TJNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? M1;aWlI3OTd4MkG5
G401 NWL4dJFOTnWwY4Tpc44hSXO|YYm= MWW1NE8yODBibl2= MXGyOEBp MnHuSG1UV8Li MVPzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v NULOcpBJOjZzN{[yNVk>
SK-NEP-1 NWXnb486TnWwY4Tpc44hSXO|YYm= NUXqfm15PTBxMUCwJI5O MkWxNlQhcA>? MYfEUXNQyqB? M2jCR4lv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh M2W4VFI3OTd4MkG5
G401 NYDL[m95TnWwY4Tpc44hSXO|YYm= M4PrXVUxNzFyMDDuUS=> M2D6N|I1KGh? MYrEUXNQyqB? NFTVSGZqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? MmLaNlYyPzZ{MUm=
RPMI 8226 MkK0R4VtdCCVdYL2bZZidCCDc4PhfS=> M{DFOlIwPC94IH7N M4Xod|Q56oDLaB?= NEjQVWVqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NUTxXlJTOjZyMECyPVI>
OPM2 M1XTUmNmdGxiU4Xyeol3[WxiQYPzZZk> MU[yM|QwPiCwTR?= NXPafGN3PDkkgJno MkXYbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NFLVZnozPjByMEK5Ni=>
U266 M{X1PGNmdGxiU4Xyeol3[WxiQYPzZZk> M1nFN|IwPC94IH7N M4DqVVQ56oDLaB?= MVrpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MV[yOlAxODJ7Mh?=
H929 M2rJfWNmdGxiU4Xyeol3[WxiQYPzZZk> MkPvNk81NzZibl2= MXW0PQKBkWh? NEPSbm5qdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NH60N4wzPjByMEK5Ni=>
RPMI 8226  MYLBdI9xfG:|aYOgRZN{[Xl? NX3kN3VFPOLCiX7N NHjG[m8zPC92ODDo NX\Y[YEycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M17UNVI3ODByMkmy
HCC827 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH0NVAhdk1? NXS0Z4w6PDhiaB?= MYPEUXNQ Mkn5[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? MVWyOVk1PDZzNx?=
NCI-H23 NYH2T|NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNEBvVQ>? MlTHOFghcA>? NGrpRY9FVVOR NHHNSHhmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= Mnu3NlU6PDR4MUe=
AML3 M{nEO2Z2dmO2aX;uJGF{e2G7 NWPZOo1IOC1zIN88US=> Mor2NlTDqGh? NXzHdGVqcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXiyVGUyOjV4MUK5OFE>
ML-1 MlrPSpVv[3Srb36gRZN{[Xl? M2fRN|AuOSEQvF2= MV6yOOKhcA>? MWnpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUKyOVYyOjl2MR?=
RPMI-8226vr10  NYXIRYNvTnWwY4Tpc44hSXO|YYm= MWiwMVEh|ryP NGS0fYEzPMLiaB?= MnnnbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnPVNlU3OTJ7NEG=
ML-1 NFLOb2ZHfW6ldHnvckBCe3OjeR?= Mkf0NUDPxE1? NHy4cHozPMLiaB?= MmLabY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= MlXVNlU3OTJ7NEG=
RPMI-8226vr10  M3;BTmZ2dmO2aX;uJGF{e2G7 Mn3vNUDPxE1? MorhNlTDqGh? NWHiZ5lbcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>? NG\nZmszPTZzMkm0NS=>
SK-N-BE (2) NFryZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Szd|I16oDLaB?= M3fIe2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= M1LjOlI2OzB6OUG2
SK-N-BE (2), PAN  MK NHzDSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILJU3YzPOLCiXi= NX\Tb217UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MomyNlU{ODh7MU[=
SK-N-BE (2), MK  PAN M32wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViyOQKBkWh? M2\4TGlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= MlHuNlU{ODh7MU[=
SK-N-AS M4GxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiyOQKBkWh? NEjucZFKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= M4TM[VI2OzB6OUG2
SK-N-DZ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vNlTjiImq M1;PfWlEPTB;MUeuNgKBkcLz4pEJNE41KG6P MnnVNlU{ODh7MU[=
Caki-1 M1TY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpNVAwOjVxNUCgcm0> NVW4bmROPDhiaB?= MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MX6yOVI4QTF7MR?=
ACHN M{jpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz4NVAwOjVxNUCgcm0> NGLzcmg1QCCq NGq3c4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MlHoNlUzPzlzOUG=
769-P MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;LbYkyOC9{NT:1NEBvVQ>? MWS0PEBp MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MYSyOVI4QTF7MR?=
786-O  M{\Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjxNVAwOjVxNUCgcm0> NVLMOo53PDhiaB?= NHvB[JVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NITyZXEzPTJ5OUG5NS=>
Caki-1 MY\BdI9xfG:|aYOgRZN{[Xl? M4j2SFUxKG6P NEXmRm41QCCq MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MnnkNlUzPzlzOUG=
ACHN NE\mcW9CeG:ydH;zbZMhSXO|YYm= MXi1NEBvVQ>? M2DFd|Q5KGh? NFi0bmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NVzwZ49XOjV{N{mxPVE>
769-P MlT0RZBweHSxc3nzJGF{e2G7 NYXmd2l4PTBibl2= NUHSZWNpPDhiaB?= NVPN[Vk{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NHH2T4YzPTJ5OUG5NS=>
786-O  NEmxXYxCeG:ydH;zbZMhSXO|YYm= NG[3b4g2OCCwTR?= MVK0PEBp NVvr[mVCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MXmyOVI4QTF7MR?=
Caki-1 NX3TeZg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTONlUwPTBibl2= NXfVNph5PDhiaB?= NXvE[FMzTE2VTx?= M33aNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NVXwfnJIOjVzN{[zOVQ>
ACHN M1rrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rrV|I2NzVyIH7N NX\JcZNRPDhiaB?= M3n2VGROW09? MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk M172ZlI2OTd4M{W0
769-P MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5NlUwPTBibl2= NHXsUlQ1QCCq MknzSG1UVw>? NWHUdWRFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> M4nCW|I2OTd4M{W0
Caki-1 NFfPRlhEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MmnKOVAhdk1? Mo\BO{0yPCCm MknGSG1UVw>? MkDZd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NXvLTJBQOjVzN{[zOVQ>
ACHN NX3GcoVKS2:ub375JGZwem2jdHnvckBCe3OjeR?= MWe1NEBvVQ>? MlrLO{0yPCCm NHHqclRFVVOR MXzzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M2n3e|I2OTd4M{W0
769-P NXjBb2twS2:ub375JGZwem2jdHnvckBCe3OjeR?= NYrtbllDPTBibl2= MnW4O{0yPCCm NGOyXmZFVVOR NH3jNox{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MkfINlUyPzZ|NUS=
Caki-1 NI\nOYtCeG:ydH;zbZMhSXO|YYm= NF;wT442OCCwTR?= NXzxZXJHPDhiaB?= NHrTO3pFVVOR MmfrbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Ml;4NlUyPzZ|NUS=
ACHN MkHnRZBweHSxc3nzJGF{e2G7 M13pN|UxKG6P Mn7rOFghcA>? NWTEcYl1TE2VTx?= M4TsVolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYfvRXpCOjVzN{[zOVQ>
769-P MVjBdI9xfG:|aYOgRZN{[Xl? NGPI[4E2OCCwTR?= NHy3OGc1QCCq NXr1[JZ5TE2VTx?= MlrKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWWyOVE4PjN3NB?=
MDA-MB-231 NVLZdlZXVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MVSxNOKhdk1? NEfRUG8{yqCm MYXEUXNQ MkXBZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NWX4TFMxOjR6MUC0PVc>
BT-549 MnjWUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 M4D6RlExyqCwTR?= NFy3bY8{yqCm M{LCdWROW09? MmrQZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi Mn:zNlQ5OTB2OUe=
MCF-7  NV7YZ4dQVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MVmxNOKhdk1? NF6weHo{yqCm NWfwZ4F6TE2VTx?= MmP5ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NXi0eWRROjR6MUC0PVc>
MCF-7 NETBSHZHfW6ldHnvckBCe3OjeR?= M4XuOVUuPTBibl2= NX7kNZZpOjRiaB?= MV7EUXNQ M4DCU5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> M4SyNVI1OzZ4NEC3
CTS M3jmVWFxd3C2b4Ppd{BCe3OjeR?= MV[w5qCUPDBibl5CpC=> M2nIOFQ5KGh? MnTpbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NX\XW2xrOjR{NES0Nlk>
OCI-AML3  MVnBdI9xfG:|aYOgRZN{[Xl? MmjqNQKBmzRyIH7NxsA> MUi0PEBp NU\4[nJLcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkfMNlQzPDR2Mkm=
U937 NXHYbJJkSXCxcITvd4l{KEG|c3H5 NF\DbG4x6oDVNECgcm3DqA>? Mn7EOFghcA>? NU[4SmNXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUXJdHE4OjR{NES0Nlk>
PC3 MojLRZBweHSxc3nzJGF{e2G7 NXPaU|c6OC1zMECgcm0> NF;ESGozPC92ODDo NX3ET4hbcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEO0e4UzPDF4M{KzNC=>
PC3-AR M1nlSGFxd3C2b4Ppd{BCe3OjeR?= MWqwMVExOCCwTR?= MorwNlQwPDhiaB?= MUjpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkHyNlQyPjN{M{C=
PC3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fXSFAuOTByIH7N MUGyOE81QCCq MYTpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v M3HKSlI1OTZ|MkOw
PC3-AR M1jqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfaXXkxNTFyMDDuUS=> MUOyOE81QCCq M4rYfolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= MXSyOFE3OzJ|MB?=
PC3 M1naemZ2dmO2aX;uJGF{e2G7 NGnteWQxNTFyMDDuUS=> NF;hWoQzPCCq MljXd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MoG4NlQyPjN{M{C=
PC3-AR Ml7OSpVv[3Srb36gRZN{[Xl? M1Pz[lAuOTByIH7N NWLuPG9IOjRiaB?= MV7zeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NEO1UW4zPDF4M{KzNC=>
OS-RC-2 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MonTNE0yODByIH7N MmH6NlQwPDhxN{KgbC=> MX7EUXNQ NWr0NXNl\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIj2TG0zPDF2NEezOy=>
OS-RC-2 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2OVAhdk1? MXW0PEBp MULEUXNQ MnfibY5lfWOnczDHNk9OKGG{cnXzeC=> NWO0bJRVOjRzNES3N|c>
OS-RC-2 M{HGeWFxd3C2b4Ppd{BCe3OjeR?= MorzOVAhdk1? NYPSfIJFPDhiaB?= MVvEUXNQ NYrt[3FDcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVWzeItoOjRzNES3N|c>
SK-N-AS NH7XR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6w5qCUQDBibl2= M13lTlQ5KGh? NXPvem45UUN3ME2yO{41KG6P MUWyOFA6QDd7OR?=
SK-N-DZ NEno[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyw5qCUQDBibl2= NVXTem1KPDhiaB?= NGiwOlZKSzVyPUKxMlkhdk1? NUO1NolnOjRyOUi3PVk>
SK-N-SH NF7QTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfsPIQx6oDVOECgcm0> NVjuVWo{PDhiaB?= M3PETWlEPTB;N{KuN{BvVQ>? NHnGbYgzPDB7OEe5PS=>
SK-N-BE NFziSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TFR|DjiJN6MDDuUS=> NXPETnI3PDhiaB?= NF70NJBKSzVyPUe1MlQhdk1? MU[yOFA6QDd7OR?=
SK-N-AS NYjWR4M{SXCxcITvd4l{KEG|c3H5 M{PLeVDjiJN6MDDuUS=> NEnhenE1QCCq NGPjNJBxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M{nvVVI1ODl6N{m5
SK-N-DZ MmH0RZBweHSxc3nzJGF{e2G7 M1\RT|DjiJN6MDDuUS=> NESzcmM1QCCq NXPxVolzeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M1e5VFI1ODl6N{m5
SK-N-SH MnPDRZBweHSxc3nzJGF{e2G7 NHXSfJIx6oDVNECgcm0> NYH5d|BZPDhiaB?= MXvwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MlHGNlQxQTh5OUm=
SK-N-BE M2nocmFxd3C2b4Ppd{BCe3OjeR?= MkD5NQKBmzRyIH7N NGrrXog1QCCq NETPe4Jxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NFLXXJAzPDB7OEe5PS=>
SK-N-AS MVjGeY5kfGmxbjDBd5NigQ>? NIjWfG4x6oDVOECgcm0> MUW0PEBp NV[0bIpscW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? M4SyXFI1ODl6N{m5
SK-N-DZ MVPGeY5kfGmxbjDBd5NigQ>? MUOw5qCUQDBibl2= M1O3blQ5KGh? M1THdolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> M{W0UFI1ODl6N{m5
SK-N-SH M1j5UGZ2dmO2aX;uJGF{e2G7 NFXNN|Ex6oDVNECgcm0> MVK0PEBp NVn6XHlRcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MnXMNlQxQTh5OUm=
SK-N-BE NGrseYNHfW6ldHnvckBCe3OjeR?= M2HjXVDjiJN2MDDuUS=> NEDGeHo1QCCq MVPpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NV3qWVNbOjRyOUi3PVk>
HCC-LM3 NVjHXXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxMVExODBibl2= MXmyOE81QC95MjDo NXvaRYhETE2VTx?= MnX5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH\4RmEzPDB7M{m1Oi=>
HepG2 NV7XfYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XafFEuOTByMDDuUS=> MXqyOE81QC95MjDo MoHUSG1UVw>? Mm\ObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2DKcVI1ODl|OUW2
SMMC-7721 M3zFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjaWJpjOS1zMECwJI5O Mn7ONlQwPDhxN{KgbC=> NFHldolFVVOR NUG3RoM5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVLpdHZROjRyOUO5OVY>
HCC-LM3 M333WWFxd3C2b4Ppd{BCe3OjeR?= M1;nNFUxKG6P NFzJe5g1QCCq MkC5SG1UVw>? MkjZbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NI\uNGIzPDB7M{m1Oi=>
HepG2 Mo\sRZBweHSxc3nzJGF{e2G7 MUG1NEBvVQ>? MkfoOFghcA>? MoXPSG1UVw>? M3\1WIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M4jH[FI1ODl|OUW2
SMMC-7721 M1\6W2Fxd3C2b4Ppd{BCe3OjeR?= Mn;TOVAhdk1? MWm0PEBp NXnvZ|VRTE2VTx?= MmrKbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> M4PpelI1ODl|OUW2
HCC-LM3 NYDIW|Y{TnWwY4Tpc44hSXO|YYm= MoHGOVAwOTByIH7N MUmyOEBp M1m1SWROW09? MmH2[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MmPRNlQxQTN7NU[=
HepG2 M3OxTWZ2dmO2aX;uJGF{e2G7 NXO5fWZ1PTBxMUCwJI5O M1\QXlI1KGh? NX70fYxITE2VTx?= NV3weZpo\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MmH5NlQxQTN7NU[=
SMMC-7721 NH;POotHfW6ldHnvckBCe3OjeR?= MlH3OVAwOTByIH7N M1zVcVI1KGh? NUi2b5BiTE2VTx?= NYXuVlhI\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NIfoRo0zPDB7M{m1Oi=>
HCC-LM3 MoqySpVv[3Srb36gRZN{[Xl? M3\yc|UxNzFyMDDuUS=> M3HzcFI1KGh? NIC5SlhFVVOR MXPkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MVyyOFA6Ozl3Nh?=
HepG2 MVLGeY5kfGmxbjDBd5NigQ>? NYjN[Ys6PTBxMUCwJI5O M2fCN|I1KGh? NEjw[GFFVVOR NWXtbVFq\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MUWyOFA6Ozl3Nh?=
SMMC-7721 M{L3c2Z2dmO2aX;uJGF{e2G7 NHfYZnM2OC9zMECgcm0> M3vNWVI1KGh? NVPjU25rTE2VTx?= NG\ONGhld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MYKyOFA6Ozl3Nh?=
FaDu M17ufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjuN|czOTBy4pEFcm0> MmOxPE8yOC9zMjDo MXfkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? M1ryWVI1ODJ4NEiy
FaDu NXTXOXlmTnWwY4Tpc44hSXO|YYm= MV:xNFDjiIWwTR?= NYK2ZXE6Oi92L{ivNVIhcA>? MX3pcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? NX;TcGU{OjRyMk[0PFI>
PC-3  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH5NE0yOCEQvF2= MmmwNlQwPDhxN{KgbC=> MmjYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWKyN|k6OTJzNh?=
LNCaP M4TaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LiXFAuPSEQvF2= NXnWXWY{OjRxNEivO|IhcA>? MlXIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHzmTJEzOzl7MUKxOi=>
RWPE-1  NYP3Ro53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\icnkxNTJyIN88US=> MmHUNlQwPDhxN{KgbC=> M3nnOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{nxbFI{QTlzMkG2
Capan-1 MnP1SpVv[3Srb36gRZN{[Xl? MVWyOU82OC9zMECgcm0> MYS4M|I1NzR6IHi= NW[0T4RQTE2VTx?= NIDTeFRld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NXTMTFFtOjN7MkK4PFY>
L3.6pl M1r2W2Z2dmO2aX;uJGF{e2G7 NVKxXnZVOjVxNUCvNVAxKG6P MlvsPE8zPC92ODDo NYLDN4J4TE2VTx?= NWm3NIwz\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MYKyN|kzOjh6Nh?=
CFPAC-1  MVPGeY5kfGmxbjDBd5NigQ>? NGO5N2gzPS93MD:xNFAhdk1? M3\XSVgwOjRxNEigbC=> NGTFUVlFVVOR M2HnTIRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= M4jPc|I{QTJ{OEi2
Capan-1 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi5SVRoOjVxNUCvNVAxKG6P M4roelQ5KGh? NUfNcox2TE2VTx?= M2nXUpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlXvNlM6OjJ6OE[=
L3.6pl MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXqOFczPS93MD:xNFAhdk1? NX\wdZJYPDhiaB?= M3zFNGROW09? NFXVcWZz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXmyN|kzOjh6Nh?=
CFPAC-1  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjSNlUwPTBxMUCwJI5O M{jHcVQ5KGh? NYPPRZozTE2VTx?= MoH2doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mlr4NlM6OjJ6OE[=
Capan-1 M2LnXWFxd3C2b4Ppd{BCe3OjeR?= Mn7kNlUwPTBxMUCwJI5O M2iyPFQ5KGh? MnjzSG1UVw>? MXLpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml3GNlM6OjJ6OE[=
L3.6pl MVrBdI9xfG:|aYOgRZN{[Xl? NI\sb5czPS93MD:xNFAhdk1? Mn\sOFghcA>? MY\EUXNQ Mlv4bY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MonCNlM6OjJ6OE[=
CFPAC-1  MWjBdI9xfG:|aYOgRZN{[Xl? MlPPNlUwPTBxMUCwJI5O Moe2OFghcA>? NGnqVHFFVVOR M4TXOYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnS5NlM6OjJ6OE[=
HN22 NX7PSXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF75eGExNTJyIH7N M1y4NVI1NzR6IHi= NFjIdZJFVVOR NXznboxNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NF35ZmczOzh5N{KzOS=>
HSC4  M3THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfyd44xNTJyIH7N NUDzeY9IOjRxNEigbC=> MVvEUXNQ NVfMOlJocW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NUnX[llqOjN6N{eyN|U>
HN22 NFfNPZlCeG:ydH;zbZMhSXO|YYm= M3PObVAuOjBibl2= NI\hO3U1QCCq NInmcJFFVVOR MVfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUmyN|g4PzJ|NR?=
HSC4  NYnvcpI6SXCxcITvd4l{KEG|c3H5 MY[wMVIxKG6P Mme1OFghcA>? NIrwUWhFVVOR NID4[lZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEnlOFAzOzh5N{KzOS=>
HN22 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5NE0zOCCwTR?= NXzRdVZMPDhiaB?= M4q5OWROW09? NXfmZ2xIcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MmfPNlM5Pzd{M{W=
HSC4  M{SzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMVIxKG6P NFS2cpU1QCCq M{nUUGROW09? MU\pcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= M4[3SFI{QDd5MkO1
HN22 M2fLXWZ2dmO2aX;uJGF{e2G7 MXiwMVIxKG6P NV\XXpJVPDhiaB?= M1fUZmROW09? MWfzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= M1K2[VI{QDd5MkO1
HSC4  M3fhbWZ2dmO2aX;uJGF{e2G7 MnrDNE0zOCCwTR?= MYG0PEBp M1foXWROW09? NF7HRZp{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NVrqWnZwOjN6N{eyN|U>
Cal62 NH3vTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvjNGpKSzVyPUOzJOKyKDRibl2= MmDNNlM5OjRyNkS=
Hth7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\HXXNKSzVyPUG1JOKyKDJibl2= MoSzNlM5OjRyNkS=
Hth83 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYNFNKSzVyPUO0JOKyKDVibl2= MX6yN|gzPDB4NB?=
C643 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD15MTFCtUAyOCCwTR?= NFfwVJkzOzh{NEC2OC=>
SW1736 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLSTWM2OD1|NTFCtUA5KG6P NW[weGJSOjN6MkSwOlQ>
T241 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\sTmlEPTB;NkWgxtEhPyCwTR?= MXeyN|gzPDB4NB?=
T351 M2LDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u4W2lEPTB;NUCgxtEhOTBibl2= NFnEVoczOzh{NEC2OC=>
BHP2-7 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7WbVZKSzVyPUO3JOKyKDZibl2= M3XLVFI{QDJ2ME[0
T238 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\4OYlKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? MUCyN|gzPDB4NB?=
HCT8 M1rVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp MkeySG1UVw>? NUT5R2h7UUN3ME2xNk466oDLwsJihKkyNjlibl2= NGP3UGkzOzJ7OUO4PC=>
H630 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NkBp NYHkZpFsTE2VTx?= Mn3MTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? NXjGTWd4OjN{OUmzPFg>
cH630 5-FU-res NY\lSVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe3NkBp M3nl[GROW09? NWfXT3JjUUN3ME2xOU426oDLwsJihKkyNjJibl2= Mmm0NlMzQTl|OEi=
HCT116 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp NEPqblZFVVOR NHjOVWRKSzVyPUGwMlfjiIoEsfMAjVIvOiCwTR?= NGXuTGwzOzJ7OUO4PC=>
HCT116 p53−/− NXfD[VNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp NWG5bIkxTE2VTx?= NV64cGh{UUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= NVrKNlQ{OjN{OUmzPFg>
dHCT116 p21−/− NIjvS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjzUFQ4OiCq MVfEUXNQ NV3VN5NmUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= NIHLd4UzOzJ7OUO4PC=>
HT29 M2C0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml70O|IhcA>? M{m4fGROW09? NUDjNohFUUN3ME2xOk4{6oDLwsJihKkzNjNibl2= NV\SUGc4OjN{OUmzPFg>
LoVo MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3NkBp NV[4cIN2TE2VTx?= Ml[zTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? NIDiV3gzOzJ7OUO4PC=>
RKO M4[zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnEO|IhcA>? NFjCflFFVVOR MYrJR|UxRTdwOfMAjeKy6oDLMj6yJI5O MkDVNlMzQTl|OEi=
SW480 NXi3NJJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fEelczKGh? MoDYSG1UVw>? NFjvVm1KSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= NUPTUVN[OjN{OUmzPFg>
eSW620 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:1OG04OiCq NGLTW2hFVVOR M4\HS2lEPTB;OT6x5qCKyrIkgJmyMlEhdk1? MnPuNlMzQTl|OEi=

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02032810 Active not recruiting Melanoma|Skin Cancer H. Lee Moffitt Cancer Center and Research Institute|Novartis January 7 2014 Phase 1
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) May 31 2018 Phase 2
NCT01169636 Completed Hodgkin''s Lymphoma M.D. Anderson Cancer Center|Novartis January 31 2011 Phase 1|Phase 2
NCT02676323 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome St. Jude Children''s Research Hospital May 3 2016 Phase 1
NCT02717455 Recruiting Glioma Pediatric Brain Tumor Consortium June 28 2016 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID